| |
The Future Is NOW for the Treatment of Chronic Myelogenous Leukemia!
Tuesday, April 22, 2008
7:00 pm – 8:30 pm (EDT)
Two Chefs Restautant
South Miami, Florida
May 2008
May 2009
90 minutes (Adobe Flash Player and Adobe Acrobat Reader required)
Accreditation Information
Target Audience
This activity has been designed to meet the
educational needs of oncologists/hematologists
caring for patients with chronic myelogenous
leukemia (CML).
Purpose
Provide education to oncology clinicians on treatment options for CML including administration and patient
education on tyrosine kinase inhibitors (TKIs) and dual
kinase inhibitors.
Program Overview
The treatment of CML dramatically changed
with the introduction of imatinib, a tyrosine
kinase inhibitor (TKI) that targets the BCR-ABL
chromosomal abnormality—a hallmark feature
of CML. Prior to the development of TKIs, the
aim of treatment was to control and palliate
patients with CML; now there is curative intent.
With the proper selection of treatments, physicians
can influence survival outcomes. Despite high
response rates to imatinib, many patients with the
chronic phase of CML will have persistent disease and
ultimately relapse. There are several options available to
patients who have relapsed or are intolerant to imatinib,
including the use of second-generation TKIs such as
dasatinib and nilotinib. With the introduction of these agents,
several new clinical questions have emerged. Should second-generation
TKIs replace imatinib as upfront therapy? What is
appropriate disease monitoring? How do you treat a patient with
increasing qPCR levels in the absence of a cytogenetic or
hematologic relapse? What are the indications for switching to
second-line therapy and what are the implications of particular
mutations on the choice of second-line therapy? How long should a
second-line TKI be used before trying other strategies? What is the role of
stem cell transplantation? In light of such new clinical questions, this program is
intended to provide attendees with a review of appropriate front-line and salvage
therapies as well as strategies for effectively monitoring response to treatment.
Attendees are invited to bring their own challenging CML patient cases for expert and
group discussions.
Learning Objectives
Upon completion of this program, participants should be better able to:
- Identify front-line therapeutic strategies for patients in the chronic phase of CML
- Describe the importance of appropriate disease monitoring, including the
relevance of an early therapeutic response
- Describe treatment options for CML in patients whose disease is resistant or
intolerant to imatinib
- Identify new investigational therapeutic strategies for CML
- Indicate when stem cell transplantation is indicated for patients with CML
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM) and IMER do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM and IMER. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications , and warnings.
Disclosure of Conflicts of Interest
Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest
The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this educational activity:
Jorge E. Cortes, MD, has a financial interest/relationship or affiliation in the form of: Consulting Fees, Bristol-Myers Squibb Company, Merck & Co., Inc., Novartis, Wyeth Pharmaceuticals, Tibotec Pharmaceuticals, Breakthrough Therapeutics, The Vaccine Company, and ChemGenex Pharmaceuticals.
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this educational activity:
Jan Hixon, RN, BSN, MA, has reported no areas of conflict.
Linda Graham, RN, has reported no areas of conflict.
Trace Hutchison, PharmD, has reported no areas of conflict.
Co-sponsored by:
|
 |
| |
Click on logo to visit site. |
|
|
|
Faculty
Jorge E. Cortes, MD
Deputy Chair, Department of Leukemia
The University of Texas, M. D. Anderson Cancer Center
Dr. Cortes is a professor of medicine and deputy chair in the Department
of Leukemia at the University of Texas, M. D. Anderson Cancer Center, in
Houston. He is also chief of the CML Section in the Department of
Leukemia. Dr. Cortes earned his doctor of medicine at the Universidad
Nacional Autonoma de Mexico in Mexico City. His clinical research is
focused on new drug development and the management of patients with
myelodysplastic syndromes, myeloproliferative disorders, as well as
acute and chronic leukemias. He has written more than 300 peer-reviewed
medical publications. Dr. Cortes has received numerous
awards including the Faculty Scholar Award from the M. D. Anderson
Cancer Center in 2003, the Annual Celgene Young Investigators
Achievement Award for Clinical Research in Hematology in 2005, and
the Kenney Award from the Leukemia and Lymphoma Society in 2006.
Privacy Policy
When you participate in a CME activity provided by the Postgraduate Institute for Medicine (“PIM” or “we”), we ask you for your name, degree, affiliation, street address, telephone number, fax number, and e-mail address (the “Information”). We use that Information in the following ways:
We use the Information to grade your post-test and to send you a certificate of completion of the CME activity. If we use a third-party company to grade your post-test and issue certificates of completion, we will give the Information to that company for that purpose only.
For each CME activity that you take, you must complete an evaluation questionnaire. That questionnaire asks if you are willing to participate in a follow-up survey. If you answer yes, we will use your name and contact information to send you the survey.
We may use the Information to invite you to participate in other CME activities that PIM or its affiliates may offer.
On occasion, the commercial supporter of a CME activity will ask us for a list of the people who participated in that activity, so that it may document the first level of outcomes-based evaluation in CME (i.e., who attended, which medical specialties/practices were represented, how this compares to the target audience, and whether the activity needs to be repeated because significant numbers of the target audience did not attend). In that event, we will provide the supporter with your name, title and affiliation, but we will request in writing that the supporter not contact you directly for any purpose.
If our company is acquired or merged into another company, we may make the Information available to the new owner/entity to use in the ways described above, to enable it to continue our business.
Any changes to our privacy policy will be posted here immediately.
Accreditation Statements
This activity has been planned and implemented in accordance with the
Essential Areas and policies of the Accreditation Council for Continuing
Medical Education (ACCME) through the joint sponsorship of PIM and
the Institute for Medical Education & Research. PIM is accredited by the
ACCME to provide continuing medical education for physicians.
Credit Designation
PIM designates this educational activity for a maximum of 1.75 AMA PRA Category 1
Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation
in the activity.
Disclaimer
Participants have an implied responsibility to use the newly acquired
information to enhance patient outcomes and their own professional
development. The information presented in this activity is not meant
to serve as a guideline for patient management. Any procedures,
medications, or other courses of diagnosis or treatment discussed or
suggested in this activity should not be used by clinicians without
evaluation of their patient’s conditions and possible contraindications
on dangers in use, review of any applicable manufacturer’s product
information, and comparison with recommendations of other
authorities.
Method of Participation
There are no fees for participating and receiving CME credit for this activity.
Participants must complete the posttest by recording the best answer to each question. Once you finished your test and completed the subsequent evaluation form, click submit test to send your responsed to us. Your test will be immediately reviewed and if you receive a passing grade of 70% or better, you will then be directed to print your certificate online.
Media
Web site |
|
